$0.103
-0.002 (-1.71%)Al cierre
Noticias de SNYR
Eventos de SNYR
Synergy CHC Receives Compliance Notice from Nasdaq
Synergy CHC announced that it received a notice from Nasdaq, indicating that the company is not in compliance with Nasdaq Listing Rule 5250 due to the delayed filing of its Quarterly Report on Form 10-Q for the quarter ended June 30 with the SEC. The listing rule requires companies with securities listed on Nasdaq to timely file all required periodic reports with the SEC. The notice has no immediate effect on the listing or trading of the company's common stock on Nasdaq.
Synergy CHC Files to Sell 101.71M Shares of Common Stock
Synergy CHC files to sell 101.71M shares of common stock for holders
Company Q4 Revenue Falls to $6.07M
Reports Q4 revenue $6.07M vs. $10.27M last year. Revenue was unfavorably impacted by the termination of a $2.9M licensing agreement. Results also reflect a $6.66M allowance for bad debt and a $1.04M write-off of obsolete inventory. "Our full year results reflect a year of meaningful strategic progress and continued advancement of our priority growth initiatives," said CEO Jack Ross
Synergy CHC Expands FOCUSfactor Product Line in Canada
Synergy CHC (SNYR) announced a major expansion of its FOCUSfactor functional beverage portfolio across Canada, building on the successful launch of FOCUSfactor's supplement SKUs at Walmart (WMT) Canada and through McKesson (MCK) Canada during Q4 2025, with sell-through and consumer feedback supporting category expansion. "This is a major milestone for FOCUSfactor as we extend our cognitive performance platform deeper into the Canadian market," said Jack Ross, CEO of Synergy CHC Corp. "Walmart Canada's expanded assortment and McKesson's national authorization further validate consumer demand for functional beverages that deliver clean energy, focus and mental clarity without the crash associated with traditional energy drinks."
Synergy CHC Appoints Pedro Colmenares as Sales & Marketing Director for Mexico & Latin America
Synergy CHC announced that Pedro Colmenares has been appointed Director of Sales & Marketing for Mexico & Latin America. In this role, Mr. Colmenares will lead commercial strategy, market expansion, and go-to-market execution across the region. Colmenares is a senior commercial executive with over 18 years of experience across the pharmaceutical, nutraceutical, OTC, and consumer health sectors.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.